Assessment of publication bias and outcome reporting bias in systematic reviews of health services and delivery research: A meta-epidemiological study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 13 09 2019
accepted: 20 12 2019
entrez: 31 1 2020
pubmed: 31 1 2020
medline: 11 4 2020
Statut: epublish

Résumé

Strategies to identify and mitigate publication bias and outcome reporting bias are frequently adopted in systematic reviews of clinical interventions but it is not clear how often these are applied in systematic reviews relating to quantitative health services and delivery research (HSDR). We examined whether these biases are mentioned and/or otherwise assessed in HSDR systematic reviews, and evaluated associating factors to inform future practice. We randomly selected 200 quantitative HSDR systematic reviews published in the English language from 2007-2017 from the Health Systems Evidence database (www.healthsystemsevidence.org). We extracted data on factors that may influence whether or not authors mention and/or assess publication bias or outcome reporting bias. We found that 43% (n = 85) of the reviews mentioned publication bias and 10% (n = 19) formally assessed it. Outcome reporting bias was mentioned and assessed in 17% (n = 34) of all the systematic reviews. Insufficient number of studies, heterogeneity and lack of pre-registered protocols were the most commonly reported impediments to assessing the biases. In multivariable logistic regression models, both mentioning and formal assessment of publication bias were associated with: inclusion of a meta-analysis; being a review of intervention rather than association studies; higher journal impact factor, and; reporting the use of systematic review guidelines. Assessment of outcome reporting bias was associated with: being an intervention review; authors reporting the use of Grading of Recommendations, Assessment, Development and Evaluations (GRADE), and; inclusion of only controlled trials. Publication bias and outcome reporting bias are infrequently assessed in HSDR systematic reviews. This may reflect the inherent heterogeneity of HSDR evidence and different methodological approaches to synthesising the evidence, lack of awareness of such biases, limits of current tools and lack of pre-registered study protocols for assessing such biases. Strategies to help raise awareness of the biases, and methods to minimise their occurrence and mitigate their impacts on HSDR systematic reviews, are needed.

Identifiants

pubmed: 31999702
doi: 10.1371/journal.pone.0227580
pii: PONE-D-19-25774
pmc: PMC6992172
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0227580

Subventions

Organisme : Department of Health
ID : 15/71/06
Pays : United Kingdom
Organisme : Department of Health
ID : HS&DR/15/71/06
Pays : United Kingdom
Organisme : Department of Health
ID : 15/71/06
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ann Oncol. 2017 May 1;28(5):931-937
pubmed: 28039176
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
PLoS Med. 2016 May 24;13(5):e1002028
pubmed: 27218655
Health Res Policy Syst. 2015 Feb 25;13:10
pubmed: 25971248
Cochrane Database Syst Rev. 2015 Dec 22;(12):CD004170
pubmed: 26694853
Int J Health Policy Manag. 2018 Feb 28;7(8):683-695
pubmed: 30078288
J Clin Epidemiol. 2018 Jan;93:45-55
pubmed: 29111471
BMC Health Serv Res. 2018 Jul 25;18(1):584
pubmed: 30045741
Br J Surg. 2017 Feb;104(3):198-204
pubmed: 28001294
Health Policy. 2015 Apr;119(4):503-10
pubmed: 25260911
Cochrane Database Syst Rev. 2013 Nov 27;(11):CD010013
pubmed: 24282112
PLoS Med. 2011 Aug;8(8):e1001081
pubmed: 21918641
Bull World Health Organ. 2004 Sep;82(9):689-96
pubmed: 15628207
J Clin Epidemiol. 2016 Dec;80:25-33
pubmed: 27502970
Am J Public Health. 2007 Feb;97(2):219-23
pubmed: 17194855
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
Cochrane Database Syst Rev. 2013 Nov 12;(11):CD002894
pubmed: 24218045
Cochrane Database Syst Rev. 2013 Nov 12;(11):CD010160
pubmed: 24218062
BMC Fam Pract. 2015 Oct 22;16:147
pubmed: 26494597
Evid Based Med. 2017 Aug;22(4):139-142
pubmed: 28701372
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007297
pubmed: 20091628
PLoS One. 2013 Jul 05;8(7):e66844
pubmed: 23861749
BMJ Open. 2017 Oct 6;7(10):e017737
pubmed: 28988181
BMJ. 2010 Aug 27;341:c4413
pubmed: 20802000
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
PLoS Med. 2011 Aug;8(8):e1001073
pubmed: 21857809
Br J Surg. 2011 Apr;98(4):469-79
pubmed: 21305537
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Syst Rev. 2012 Jun 09;1:28
pubmed: 22681772
BMJ. 2010 Feb 15;340:c365
pubmed: 20156912
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007458
pubmed: 22786507
PLoS One. 2007 Dec 26;2(12):e1350
pubmed: 18159233
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
Health Technol Assess. 2010 Feb;14(8):iii, ix-xi, 1-193
pubmed: 20181324

Auteurs

Abimbola A Ayorinde (AA)

Warwick Centre for Applied Health Research and Delivery, University of Warwick, Coventry, England, United Kingdom.

Iestyn Williams (I)

Health Services Management Centre, University of Birmingham, Birmingham, England, United Kingdom.

Russell Mannion (R)

Health Services Management Centre, University of Birmingham, Birmingham, England, United Kingdom.

Fujian Song (F)

Department of Population Health and Primary Care, University of East Anglia, Norwich, England, United Kingdom.

Magdalena Skrybant (M)

Institute of Applied Health Research, University of Birmingham, Birmingham, England, United Kingdom.

Richard J Lilford (RJ)

Warwick Centre for Applied Health Research and Delivery, University of Warwick, Coventry, England, United Kingdom.

Yen-Fu Chen (YF)

Warwick Centre for Applied Health Research and Delivery, University of Warwick, Coventry, England, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH